Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447262 | 0.86 | TSHR (0.56) | TSHRMAOBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11146323 | 0.82 | TSHR (0.67) | TSHRKDM4EPOLBNAAACA1 | |
| Biphenyl SCHEMBL27837369 | 0.81 | TSHR (0.50) | TSHRMAOBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26812996 | 0.79 | TSHR (0.48) | TSHRMAOBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26813025 | 0.79 | TSHR (0.48) | TSHRMAOBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1344130 | 0.78 | ALDH1A1 (0.37) | TSHRCYP3A4 | |
| SCHEMBL21415433 | 0.77 | TSHR (0.50) | TSHRKDM4EPOLBCYP3A4NAAA | |
| SCHEMBL13813150 | 0.75 | ALDH1A1 (0.35) | — | |
| SCHEMBL3648830 | 0.75 | TSHR (0.52) | TSHRMAOBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16248689 | 0.75 | KDM4E (0.53) | TSHRKDM4EPOLBCHRM3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173305-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | US | disclosed |
| EP-3813946-B1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-22 | — | — | EP | disclosed |
| CN-117843659-A | Rapamycin analogues and uses thereof | 詹森药业有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11944605-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-02 | — | — | US | disclosed |
| EP-4302827-A2 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN Pharmaceutica NV (BE) | 2024-01-10 | — | — | EP | disclosed |
| CN-112423843-B | Rapamycin analogues and uses thereof | 詹森药业有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20210220339-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-22 | — | — | US | disclosed |
| US-20210220339-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-22 | — | — | US | disclosed |
| EP-3813946-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10980784-B2 | Rapamycin analogs and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980784-B2 | Rapamycin analogs and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112423843-A | Rapamycin analogs and uses thereof | 纳维托制药有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980784-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | TSHR 3810/4885KDM4E 1565/4885POLB 3464/4885 |
| US-20210220339-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | TSHR 3810/4885KDM4E 1565/4885POLB 3464/4885 |
| US-11944605-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | TSHR 3810/4885KDM4E 1565/4885POLB 3464/4885 |
| US-20240173305-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | TSHR 3810/4885KDM4E 1565/4885POLB 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.